3286-55-3

Basic information

• Product Name: 6-CHLORO-4-AMINO-2-METHOXYPYRIMIDINE
• Synonyms: 6-CHLORO-4-AMINO-2-METHOXYPYRIMIDINE;4-Amino-6-chloro-2-methoxypyrimidine
• CAS NO: 3286-55-3
• Molecular Formula: C₅H₆ClN₃O
• Molecular Weight: 159.58
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 3286-55-3.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 337.8ºC at 760 mmHg
• Flash Point: 158.1ºC
• Appearance: /
• Density: 1.398g/cm3
• Vapor Pressure: 0.000102mmHg at 25°C
• Refractive Index: 1.585
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 6-CHLORO-4-AMINO-2-METHOXYPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-4-AMINO-2-METHOXYPYRIMIDINE(3286-55-3)
• EPA Substance Registry System: 6-CHLORO-4-AMINO-2-METHOXYPYRIMIDINE(3286-55-3)

Safety Data

• Hazardous Substances Data: 3286-55-3(Hazardous Substances Data)

Usage

General Description

6-Chloro-4-amino-2-methoxypyrimidine is a chemical compound with the molecular formula C5H6ClN3O. It is a pyrimidine derivative that contains a chloro and amino group on the 6th and 4th carbon atoms, respectively, as well as a methoxy group on the 2nd carbon atom. 6-CHLORO-4-AMINO-2-METHOXYPYRIMIDINE is commonly used in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It has potential applications in the development of new drugs and pesticides due to its structural characteristics and reactivity. Additionally, it may also be used as a building block in organic synthesis and chemical research.

InChI:InChI=1/C5H6ClN3O/c1-10-5-8-3(6)2-4(7)9-5/h2H,1H3,(H2,7,8,9)

Upstream product

• 10132-07-7 4-amino-2,6-dichloropyrimidine 
• 124-41-4 sodium methylate 

Relevant articles and documents

SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN

The present invention provides a compound of formula (I): Y-J-NH-Z wherein: Y is a quinoline or isoquinoline optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; J is pyridine, pyridazine, pyrazine, pyrimidine or triazine optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C3-5cycloalkyl, C1-4alkoxy, hydroxyC1-4alkyl, cyano, hydroxy, C1-4cycloalkoxy, C1-4alkylthio, haloC1-4alkoxy, nitro, Q, (CH2)pQ, NR2R3, -(CH2)pNR2R3 and -O(CH2)pNR2R3; wherein J is substituted at positions meta to each other by NH and Y; and Z is phenyl or pyridyl optionally substituted with one or two substituents independently selected from halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; Q is phenyl, a five-membered heterocyclic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, or a six-membered heterocyclic ring containing one, two or three nitrogen atoms, optionally substituted by C1-4alkyl; each R2 and R3 is chosen from H and C1-4alkyl, or R2 and R3, together with the nitrogen atom to which they are attached, may form a six-membered ring optionally containing an oxygen atom or a further nitrogen atom, which ring is optionally substituted by C1-4alkyl or Q; p is 1, 2 or 3; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in methods of therapy; use of it for manufacturing medicaments; and methods of using it to treat diseases requiring administration of a VR1 antagonist such as pain, cough, GERD and depression.